NNNN (Anbio Biotechnology) EBIT: $5.77 Mil (TTM As of Dec. 2025)


NNNN Anbio Biotechnology NNNN
24 GF Score
Price $12.46
! 2 Warning Signs
View Full Analysis

What is Anbio Biotechnology EBIT?

Anbio Biotechnology NNNN +2.88% 24 EBIT is $5.77 Mil as of Dec. 2025. GuruFocus rates NNNN with a GF Score™ of 24/100. The stock has 2 warning signs investors should review.

Anbio Biotechnology's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was $2.40 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was $5.77 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Anbio Biotechnology's annualized ROC % for the quarter that ended in Dec. 2025 was 29.59%. Anbio Biotechnology's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 29.65%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Anbio Biotechnology's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 1.08%.

Anbio Biotechnology  (NAS:NNNN) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Anbio Biotechnology's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=4.8 * ( 1 - 0% )/( (14.192 + 18.254)/ 2 )
=4.8/16.223
=29.59 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=27.681 - 0.06 - ( 13.429 - max(0, 0.131 - 27.681+13.429))
=14.192

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=30.243 - 0.088 - ( 11.901 - max(0, 0.088 - 30.243+11.901))
=18.254

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Anbio Biotechnology's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=4.8/( ( (0 + max(14.121, 0)) + (0 + max(18.253, 0)) )/ 2 )
=4.8/( ( 14.121 + 18.253 )/ 2 )
=4.8/16.187
=29.65 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(3.716 + 0 + 10.536) - (0.06 + 0 + 0.071)
=14.121

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(3.656 + 0 + 14.685) - (0.088 + 0 + 0)
=18.253

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Anbio Biotechnology's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=5.767/534.983
=1.08 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anbio Biotechnology EBIT Related Terms

Anbio Biotechnology EBIT Historical Data

* Premium members only.

The historical data trend for Anbio Biotechnology's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anbio Biotechnology EBIT Chart

Anbio Biotechnology Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
2.54 10.02 1.96 2.00 5.77

Anbio Biotechnology Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only 0.54 3.60 -1.60 3.37 2.40

NNNN vs ANGO, OSUR, UTMD: EBIT Comparison

For the Medical Instruments & Supplies subindustry, Anbio Biotechnology's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Anbio Biotechnology EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Anbio Biotechnology's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Anbio Biotechnology's EV-to-EBIT falls into.


NNNN
24GF Score
Anbio Biotechnology NNNN
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anbio Biotechnology EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $5.77 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $5.77 Mil mean?
Anbio Biotechnology (NNNN) has a EBIT of $5.77 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Anbio Biotechnology.
Is Anbio Biotechnology's EBIT too high?
Anbio Biotechnology's current EBIT is $5.77 Mil. Overall, Anbio Biotechnology has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Anbio Biotechnology's EBIT compare to ANGO and OSUR?
Anbio Biotechnology's EBIT of $5.77 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Anbio Biotechnology. Anbio Biotechnology's current EBIT is $5.77 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anbio Biotechnology stock overvalued right now?
Anbio Biotechnology (NNNN) has a current EBIT of $5.77 Mil. The current EBIT is $5.77 Mil. Anbio Biotechnology's overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Anbio Biotechnology (NNNN), the current EBIT is $5.77 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Anbio Biotechnology Business Description

Address Friedrich-Ebert-Anlage 35-37, Frankfurt am Main, HE, DEU, 60327
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).
24GF Score

Get the complete analysis for NNNN

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.46
Price